Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

11.49 +0.03 (+0.26%)
Streaming Delayed Price Updated: 3:04 PM EDT, Aug 8, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 316,761
Open 11.44
Bid (Size) 11.48 (3)
Ask (Size) 11.49 (2)
Prev. Close 11.46
Today's Range 11.19 - 11.68
52wk Range 6.910 - 50.54
Shares Outstanding 49,084,068
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. 
Via Benzinga
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire

Performance

YTD
-67.47%
-67.47%
1 Month
+19.44%
+19.44%
3 Month
+30.27%
+30.27%
6 Month
-58.96%
-58.96%
1 Year
-76.58%
-76.58%

More News

Read More
3 Biotech Stocks to Buy Before They Boom
Via InvestorPlace
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Protagonist Therapeutics Shares Are Crashing Today
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Via InvestorPlace
Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
71 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks Flounder As Wall Street Rotates Out Of Tech
Via Talk Markets
Mid-Day Market Update: Nasdaq Down 400 Points; Arch Resources Shares Jump
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Via Talk Markets
Futures Slide Ahead Of Tech Earnings Deluge
Via Talk Markets
Mid-Morning Market Update: Markets Open Lower; Dow Dips 300 Points
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.